Abstract
To improve cure rates for neuroblastoma (NB), it is important and necessary to evaluate therapy response. Our investigation focuses on using plasma cell free DNA (cfDNA) as a biomarker to determine tumor burden and minimal residual disease (MRD) of NB patients during chemotherapy. Total 58 NB patients were recruited from July 2016 to December 2017. Therapy regime and risk classification were based on COG standard and BCH-NB-2007 protocol. RECIST study was used to judge response to therapy at the end of fourth cycle of chemotherapy (CC4) and maintenance stage (MS) respectively. Serial quantifications of cfDNA, NSE, and LDH were examined at four stages, including newly diagnosed, second and CC4, and maintenance. During early chemotherapy, 65.5% of NB kids responded well. Consistently, cfDNA, NSE, and LDH levels were down-regulated in NB patients with partial remission (PR) compared to those with stable disease (SD). In both training and predicting sets, the levels of cfDNA were significantly comparable between PR and SD only at CC4 stage. To predict the insufficient response to early chemotherapy, the optimal AUC value of cfDNA was 0.732 and 0.747 in training and predicting sets respectively, with a sensitivity of 63.2% and 80% s...Continue Reading
References
Apr 18, 2003·American Journal of Hematology·Michael Y ShapiraReuven Or
Jul 28, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Miep A van der DriftFrederik B J M Thunnissen
Jan 1, 2010·Experimental and Therapeutic Medicine·Shinobu TomochikaMasaaki Oka
Dec 2, 2014·Pediatric Clinics of North America·Meredith S Irwin, Julie R Park
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nai-Kong V CheungIrene Y Cheung
May 6, 2015·Pediatric Blood & Cancer·Esther M van WezelUNKNOWN GPOH MRD Study Group
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Navin R PintoSusan L Cohn
Sep 22, 2015·Journal of Pediatric Surgery·Sho KuriharaEiso Hiyama
Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B T LiC G Azzoli
Jan 2, 2016·Oncology Letters·Nobuyuki YamamotoNoriyuki Nishimura
Jan 14, 2016·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Susan E SharpMichael J Gelfand
Jul 15, 2016·British Journal of Cancer·Irene TadeoRosa Noguera
Jul 26, 2016·Oncology Letters·Satoshi HiraseNoriyuki Nishimura
Aug 20, 2016·JAMA Oncology·Geoffrey R OxnardLynette M Sholl
Mar 12, 2017·Journal of Cancer Research and Clinical Oncology·Jiaoyang CaiJingyan Tang
Apr 4, 2017·Cancer Cell International·Zhi-Xia YueXiao-Li Ma
Jul 1, 2017·Pediatric Hematology and Oncology·Atif A AhmedMaxine Hetherington
Jul 12, 2017·Cancer·Kevin CampbellSteven G DuBois
Aug 9, 2017·Paediatric Drugs·Frank BertholdFritz Lampert
Sep 9, 2017·Cancer·Wendy B LondonJulie R Park
Oct 13, 2017·Journal of Pediatric Surgery·Martin DübbersGrigore Cernaianu
Jan 18, 2018·Breast Cancer Research and Treatment·Jie ChengBarbara Burwinkel
Feb 6, 2018·Clinical Nuclear Medicine·Bin LiuHongming Zhuang
Apr 19, 2018·Annals of Nuclear Medicine·Hiroaki IshiguchiShinji Naganawa
Nov 9, 2018·Science Translational Medicine·Florent MouliereNitzan Rosenfeld
Citations
Jul 31, 2020·Pediatric Blood & Cancer·Meng WeiRui Dong
Sep 9, 2020·Molecular Oncology·Yan SuXiaoli Ma
May 23, 2020·Cancer Management and Research·Yuejiao ZhongJianwei Lu
Feb 8, 2020·BMC Cancer·Yan SuXiaoli Ma
Jun 10, 2021·Pediatric Hematology and Oncology·Fu-Yi ZhuQiang Zhao
Nov 10, 2021·Pediatric Hematology and Oncology·Hongjun FanXiaoli Ma